USA - NASDAQ:PROF - CA74319B5027 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to PROF. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-23 | Lake Street | Maintains | Buy -> Buy |
| 2024-07-16 | Stifel | Upgrade | Hold -> Buy |
| 2024-03-11 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-03-08 | Stifel | Maintains | Hold -> Hold |
| 2024-01-04 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-11-28 | Stifel | Initiate | Hold |
| 2023-08-04 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2023-05-11 | TD Cowen | Maintains | Outperform |
| 2023-05-11 | Alliance Global Partners | Maintains | Buy |
| 2023-03-21 | Jefferies | Downgrade | Buy -> Equal-Weight |
| 2022-11-04 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-03-07 | Cowen & Co. | Maintains | Outperform |
| 2022-02-22 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2021-07-28 | Raymond James Financial | Initiate | Strong Buy |
| 2021-05-13 | Raymond James Financial | Upgrade | Strong-Buy |
| 2021-03-10 | Raymond James Financial | Initiate | STRONG BUY |
| 2021-02-26 | Raymond James Financial | Reiterate | Strong Buy |
6 analysts have analysed PROF and the average price target is 11.31 USD. This implies a price increase of 75.1% is expected in the next year compared to the current price of 6.46.
The consensus rating for PROFOUND MEDICAL CORP (PROF) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.